p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma

p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma

Abstract Background Lung cancer is still the main cause of cancer death worldwide despite the availability of targeted therapies and immune-checkpoint inhibitors combined with chemotherapy. Cancer cell heterogeneity and primary or acquired resistance mechanisms cause the elusive behaviour of this ca...

Full description

Bibliographic Details
Main Authors: Federica Giordano, Valentina Vaira, Diego Cortinovis, Sara Bonomo, Joyce Goedmakers, Federica Brena, Annamaria Cialdella, Leonarda Ianzano, Irene Forno, Maria Grazia Cerrito, Roberto Giovannoni, Gian Luca Ferri, Ennio Tasciotti, Silve Vicent, Francesco Damarco, Silvano Bosari, Marialuisa Lavitrano, Emanuela Grassilli
Format: Article
Language:English
Published: BMC 2019-06-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
NSCLC
Drug resistance
p65BTK
BTK inhibitors
EGFR
EGFR inhibitors
Online Access:http://link.springer.com/article/10.1186/s13046-019-1199-7

Internet

http://link.springer.com/article/10.1186/s13046-019-1199-7

Similar Items